The particulars: oral semaglutide · a wide-pore C18 column · liraglutide.
I am trying to choose between two options that are usually discussed as though only one exists.
I am not optimising for price, but I am not indifferent to it either.
Which axes does this decision turn on?
High-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."
Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.
On the detail: detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.
Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.
The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.
The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.
edited 5 Jul 2025 by h_pergande — removed a claim I could not source
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsSystem suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.
Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.
It helps to be literal here: acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
Worth being precise here: the chemistry of peptides at low pH and high organic-solvent concentration is not something most users have intuition for, which is why published methods exist.
Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.
Temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.
Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.
Ask for the chromatogram and the system suitability data, not just the number.
To be exact about it, reverse-phase HPLC is the workhorse for peptide purity work, but it is almost universally run under conditions that are not optimal for a peptide of this chain length.
Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.
The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.
One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.
The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.
The underlying point is that coupling the chromatography to mass spectrometry adds identity information but trades chromatographic quality for ionisation efficiency.
Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.
I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
edited 6 Jun 2025 by lipid_panel_q — expanded the table to cover the lower concentration
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.